Related Experiment Video
Updated: Jan 31, 2026
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Engineering stimuli-responsive extracellular vesicles for enhanced anticancer therapeutics
Brian I Molina Diaz1, Pei Zhuang1, Xiaoshu Pan1
1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Abstract:
Extracellular vesicles (EVs), so called nano-sized vesicles shedding out from cells, have emerged as promising nanocarriers for cancer therapy given their high biocompatibility and low immunogenicity. However, their clinical utility remains limited by challenges such as off-target, premature drug release, and rapid clearance. In solid tumors, these issues are further compounded by the hostile biomechanical environment, including stiff extracellular matrix (ECM), elevated interstitial fluid pressure (IFP), and abnormal vasculatures, further complicates drug delivery and therapeutic efficacy. To overcome these limitations, recent efforts have focused on engineering stimuli-responsive EVs that respond to internal stimuli (e.g., pH, enzymatic activity, redox imbalance) or external stimuli (e.g., magnetic fields, light, ultrasound, temperature), as well as combinations thereof. These smart nanoplatforms have demonstrated a superior capacity in achieving controlled drug release, enhancing tumor targeting, and improving deep tissue penetration. In this minireview, we highlight how stimuli-responsive EVs surpass tumor biomechanics for cancer therapy and discuss key considerations for future development and clinical translation.
Insights
Stimuli-responsive extracellular vesicles (EVs) overcome tumor biomechanics for improved cancer therapy. These engineered nanocarriers enhance drug delivery, targeting, and penetration, addressing limitations of current treatments.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapeutics
Background:
- Extracellular vesicles (EVs) are promising nanocarriers for cancer therapy due to biocompatibility and low immunogenicity.
- Clinical application is hindered by off-target delivery, premature drug release, rapid clearance, and the challenging tumor microenvironment (e.g., stiff ECM, high IFP).
Purpose of the Study:
- To review how stimuli-responsive EVs can overcome tumor biomechanical barriers for enhanced cancer therapy.
- To discuss the development and clinical translation of these advanced nanoplatforms.
Main Methods:
- Engineering of EVs to be responsive to internal stimuli (pH, enzymes, redox) or external stimuli (magnetic fields, light, ultrasound, temperature).
- Evaluation of engineered EVs for controlled drug release, enhanced tumor targeting, and improved deep tissue penetration.
Main Results:
- Stimuli-responsive EVs demonstrate superior control over drug release kinetics.
- Engineered EVs show enhanced accumulation and efficacy within solid tumors.
- These nanoplatforms exhibit improved deep tissue penetration compared to conventional methods.
Conclusions:
- Stimuli-responsive EVs offer a viable strategy to overcome the biomechanical challenges of solid tumors.
- Further development and clinical translation are crucial for realizing the full therapeutic potential of engineered EVs in cancer treatment.
Related Concept Videos
01:36Humoral Immune Responses
00:49What is Genetic Engineering?
01:42The Extracellular Matrix
01:13Therapeutic Index
03:00Self-Evaluation: Self-Enhancement and Self-Verification
01:16Bioavailability Enhancement: Drug Solubility Enhancement